RedHill Biopharma Ltd. RDHL
0.28 USD -0.04 (-13.08%)
Regular-session close
0.29 0.00 +1.78%
After hours · Nov 20, 4:00 PM ET
0.281 Day range 0.3385
0.281 52-week range 1.40
- YTD
- -72.72%
- 1 year
- -72.98%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock increased by 16.4% to $3.82 during Friday's after-market session. The market value of their outstanding shares is at $16.1 million. Spectral AI…benzinga.com RedHill Biopharma Highlights Growth Opportunities Following Talicia Divestiture, Portfolio Expansion RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Guy Goldberg, Chief Business Officer of RedHill Biopharma, participated…
prnewswire.com RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment Chief Business Officer, Guy Goldberg, discusses the Company's evolution into a more scalable commercial-stage business, opportunities to drive growth across its expanded GI portfolio and its…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their…benzinga.com Redhill Biopharma Announced Confirmation Of RHB-204's Killing Capability On Mycobacterium Avium Subspecies Paratuberculosis And Its Comparability To RHB-104 MAP-Killing In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to…
prnewswire.com Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
prnewswire.com $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
defenseworld.net Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL) Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
prnewswire.com RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5…
defenseworld.net Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS) Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on…
prnewswire.com RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI)…
prnewswire.com RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path…
prnewswire.com Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing,…
prnewswire.com RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement $6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ --…
prnewswire.com RedHill Biopharma Announces Up To $19.4 Million Private Placement $6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ --…
prnewswire.com RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young…
prnewswire.com RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
prnewswire.com RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively…
globenewswire.com Bessor Announces Entering Option for the Redhill Property Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement”)…
prnewswire.com RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium…
prnewswire.com RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights 2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization…
prnewswire.com RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on…
defenseworld.net Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both medical companies, but which is the superior investment?…
defenseworld.net Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200-Day Moving Average – What’s Next? Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.27 and traded as…
